Pharmaxis
Market Cap
AU$46.4m
Last Updated
2020/02/16 10:31 UTC
Data Sources
Company Financials +
Executive Summary
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with concerning outlook.
Share Price & News
How has Pharmaxis's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PXS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
6.4%
PXS
-2.7%
AU Pharmaceuticals
1.4%
AU Market
1 Year Return
-55.0%
PXS
-15.1%
AU Pharmaceuticals
16.1%
AU Market
Return vs Industry: PXS underperformed the Australian Pharmaceuticals industry which returned -15.1% over the past year.
Return vs Market: PXS underperformed the Australian Market which returned 16.1% over the past year.
Shareholder returns
| PXS | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.4% | -2.7% | 1.4% |
| 30 Day | -19.3% | -4.1% | 0.8% |
| 90 Day | -51.2% | -6.3% | 4.4% |
| 1 Year | -55.0%-55.0% | -14.9%-15.1% | 21.2%16.1% |
| 3 Year | -61.0%-61.0% | -32.0%-32.6% | 37.0%18.6% |
| 5 Year | 25.8%25.8% | -23.9%-28.9% | 51.7%17.8% |
Price Volatility Vs. Market
How volatile is Pharmaxis's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
We Think Pharmaxis (ASX:PXS) Can Afford To Drive Business Growth1 month ago | Simply Wall St
Volatility 101: Should Pharmaxis (ASX:PXS) Shares Have Dropped 46%?2 months ago | Simply Wall St
What Type Of Shareholder Owns Pharmaxis Ltd's (ASX:PXS)?Valuation
Is Pharmaxis undervalued compared to its fair value and its price relative to the market?
9.18x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PXS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PXS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PXS is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: PXS is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PXS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PXS is overvalued based on its PB Ratio (9.2x) compared to the AU Pharmaceuticals industry average (3.5x).
Next Steps
Future Growth
How is Pharmaxis forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
28.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PXS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PXS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PXS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PXS's revenue (8.8% per year) is forecast to grow faster than the Australian market (4.1% per year).
High Growth Revenue: PXS's revenue (8.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PXS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Pharmaxis performed over the past 5 years?
-13.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PXS is currently unprofitable.
Growing Profit Margin: PXS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PXS is unprofitable, and losses have increased over the past 5 years at a rate of -13% per year.
Accelerating Growth: Unable to compare PXS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PXS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.3%).
Return on Equity
High ROE: PXS has a negative Return on Equity (-353.47%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Pharmaxis's financial position?
Financial Position Analysis
Short Term Liabilities: PXS's short term assets (A$30.0M) exceed its short term liabilities (A$7.4M).
Long Term Liabilities: PXS's short term assets (A$30.0M) exceed its long term liabilities (A$29.8M).
Debt to Equity History and Analysis
Debt Level: PXS is debt free.
Reducing Debt: PXS has no debt compared to 5 years ago when its debt to equity ratio was 0.02%.
Balance Sheet
Inventory Level: PXS has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if PXS's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PXS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PXS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Pharmaxis's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate PXS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PXS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PXS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PXS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PXS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.2yrs
Average management tenure
CEO
Gary Phillips (58yo)
6.9yrs
Tenure
AU$613,487
Compensation
Mr. Gary Jonathan Phillips, BPharm, MBA has been Chief Executive Officer and Managing Director of Pharmaxis Ltd. since March 12, 2013 and served as its Chief Operating Officer from November 2003 to March 2 ...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD412.21K) is above average for companies of similar size in the Australian market ($USD254.67K).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 6.9yrs | AU$613.49k | 0.59% A$273.3k | |
| CFO & Company Secretary | 17.2yrs | AU$494.95k | 0.23% A$106.9k | |
| Head of Drug Discovery | 7.5yrs | AU$485.99k | 0.16% A$73.0k | |
| General Counsel | 0yrs | no data | no data | |
| Head of Chemistry for Drug Discovery | 2.3yrs | no data | no data |
7.2yrs
Average Tenure
56.5yo
Average Age
Experienced Management: PXS's management team is seasoned and experienced (7.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 6.9yrs | AU$613.49k | 0.59% A$273.3k | |
| Independent Chairman of the Board | 7.8yrs | AU$100.00k | 0.17% A$79.9k | |
| Member of Scientific Advisory Board | 0yrs | AU$711.06k | no data | |
| Non Executive Director | 11.7yrs | AU$70.00k | 0.014% A$6.3k | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Non Executive Director & Member of Scientific Advisory Board | 2.3yrs | AU$70.00k | 0.0051% A$2.4k | |
| Non-Executive Director | 1.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Member of Scientific Advisory Board | 0yrs | no data | no data | |
| Member of Scientific Advisory Board | 0yrs | no data | no data |
4.6yrs
Average Tenure
63yo
Average Age
Experienced Board: PXS's board of directors are considered experienced (4.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.
Top Shareholders
Company Information
Pharmaxis Ltd's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Pharmaxis Ltd
- Ticker: PXS
- Exchange: ASX
- Founded: 1998
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$46.381m
- Shares outstanding: 394.73m
- Website: https://www.pharmaxis.com.au
Number of Employees
Location
- Pharmaxis Ltd
- 20 Rodborough Road
- Frenchs Forest
- New South Wales
- 2086
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PMXS.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Nov 2003 |
| PXS | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Nov 2003 |
| UUD | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Nov 2003 |
| PXS | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Nov 2003 |
| UUD | BRSE (Berne Stock Exchange) | Yes | Ordinary Shares | CH | CHF | Nov 2003 |
| PXSL.Y | OTCPK (Pink Sheets LLC) | SPON ADR | US | USD | Jul 2004 |
Biography
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company’s drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, pulmonary fibrosis, liver, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO/MPO inhibitor programs. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/16 10:31 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.